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Methods
We scrutinized systematic reviews of the Cochrane Database (Issue 4, 2009) and meta-analyses published in four general journals (2008-09). Eligible articles included 51 binary outcome metaanalysis(es) pertaining to effectiveness with 51 clinical trial(s) published in NEJM, JAMA or Lancet. Effect sizes in trials from NEJM, JAMA or Lancet were compared with those from other trials in the same meta-analyses by deriving summary relative odds ratios (sRORs). Additional analyses examined separately early-and late-published trials in HIG journals and journal-specific effects.
Results
A total of 79 meta-analyses including 1043 clinical trials were analysed. Trials in HIG journals had similar effects to trials in other journals, when there was large-scale evidence, but showed more favourable results for experimental interventions when they were small. When HIG trials had less than 40 events, the sROR was 1.64 [95% confidence interval (95% CI): 1.23-2.18). The difference was most prominent when small early trials published in HIG journals were compared with subsequent trials [sROR 2.68 (95% CI: 1.33-5.38)]. Late-published HIG trials showed no consistent inflation of effects. The patterns did not differ beyond chance between NEJM, JAMA or Lancet.
Introduction
For the past several decades, a few medical journals have concentrated most of the clinical trials that draw public and scientific attention and are highly cited. 1 However, some highly cited trials are subsequently found to have exaggerated results. 2 Given the high degree of competition for limited publication space, journals with the highest impact factors selectively publish the most groundbreaking, informative findings. 3 Results, size, timing and research context may influence which trials appear in these journals and may cause complex selection biases. 4, 5 'Negative' trials may be less likely to be published in major journals, 6 although not all evidence agrees on this bias. 7 Major journals may not publish small trials unless they are the first for an important question or find significant results with major implications; and such early trials with significant results may have inflated estimates of treatment effects. [8] [9] [10] [11] Moreover, 'negative' trials may be published with delay 12 and major journals may not publish late 'negative' trials unless they are very large and/or they decisively modify previous evidence. 13 Do such selection forces eventually bias the literature of high-impact general (HIG) medical journals and, if so, by how much? Here, we sought to examine whether trials published in the three most influential general medical journals yield larger effect sizes favouring new interventions. We evaluated whether exaggeration of effect sizes affects mostly small trials and early published trials and whether it varies across these three journals.
Methods Definitions
We considered as HIG medical journals the three general medical journals with the highest impact factors per Journal Citation Reports (2008): 14 NEJM, JAMA and Lancet. These journals have the largest impact factors (50, 31.7 and 28.4, respectively) among journals that publish clinical trials and have topped the impact factor list for many years, despite some variability over time. 15 All other journals, along with other types of literature comprise the control group.
Search strategy and eligible meta-analyses
We aimed to identify meta-analyses of randomized trials that included 51 trial published in a HIG journal and 51 trial from a control publication venue in calculating a summary effect. We searched the Cochrane Database of Systematic Reviews (CDSR) (Issue 4, 2009) for reviews mentioning anywhere the terms New England Journal of Medicine, NEJM, N Engl J Med, Journal of the American Medical Association, JAMA, J Am Med Assoc, or Lancet. We also evaluated all meta-analyses of randomized trials published in JAMA, Lancet, Annals of Internal Medicine and BMJ (general medical journals that publish a lot of metaanalyses) from January 2008 to December 2009. Using the ISI Web of Science database, we scrutinized the references of these meta-analysis papers and determined whether any trial from a HIG journal was referenced. Subsequently, eligibility was firmly established by full-text evaluation of the metaanalyses. We excluded reviews that performed no quantitative synthesis, withdrawn reviews, methodological reviews and reviews that were still in protocol stage.
For consistency, we considered only meta-analyses for binary outcomes as defined and selected by the meta-analysts and pertaining to the effectiveness of an intervention vs placebo, no treatment or an older intervention. We excluded meta-analysis articles with only continuous outcomes, only safety outcomes and those not providing number of events and allocated participants per arm in each trial.
When a review included eligible meta-analyses on more than one comparison, we considered these separately. When there were several meta-analyses for the same comparison but different outcomes, we selected the primary outcome chosen by the reviewers. When primary outcomes were multiple or nonspecified, we applied the following criteria in order of priority: select the meta-analysis with a larger number of trials; the one with a larger number of events; the one presented first in the review. We considered all trials included in each meta-analysis, regardless of their characteristics and quality (e.g. whether randomization or allocation concealment were adequate or not).
Data extraction and analysis
For each eligible meta-analysis paper, we recorded whether the authors used any of the following criteria for inclusion of trials: articles in English only, minimum sample size, minimum event count and minimum methodological quality score. For each trial included in each eligible meta-analysis, we recorded the sample size, number of participants with an unfavourable outcome in each treatment arm, journal and publication year. Data were coded so as to represent consistently comparisons of experimental/new intervention vs placebo/no treatment/older intervention for unfavourable outcomes. Thus an odds ratio (OR) <1 indicates that the new/experimental intervention is better than the comparator intervention. For each meta-analysis, we estimated separately the OR for trials from HIG journals and for trials in other publication venues. Whenever there were 52 trials, data were combined with random-effects calculations. 16, 17 We further calculated the relative odds ratio (ROR) within each meta-analysis as the ratio of the summary OR of trials in other venues to the summary OR of trials published in HIG journals. ROR41 means that HIG journal trials show more favourable results for new/experimental interventions compared with other publication venues. We hypothesized that trials published in HIG journals may yield different results from those in other venues when trials in the HIG journals are small, whereas differences may not exist with large-scale evidence. The combination of ROR data from all meta-analyses would be driven by the meta-analyses with large-scale evidence. Therefore, we grouped meta-analyses according to tertile cut-offs for the number of events in trials published in HIG journals, considering an event the less common of the two possible outcomes across all trials published in HIG journals (<40, 40-361, 4361 events). We then synthesized the ROR values to obtain a summary ROR (sROR) in each tertile. sROR values were compared across tertiles with analysis of variance adjusted for trend. For trials from HIG journals in meta-analyses of the first tertile (<40 events), we recorded whether they reported that they had been stopped early for benefit. For the first tertile, we also performed an additional analysis restricted to meta-analyses with an equally small number of events in non-HIG trials.
In another subgroup analysis, we compared trials from HIG journals regardless of size vs non-HIG trials with a small number of events (<40). Analyses using tertiles of the weight (1/variance) of the evidence yielded similar categorizations (correlation coefficient between weight and number of events ¼ 0.81) and similar results (data not shown). We examined whether the effect of inflation in small trials does not affect only HIG journals. Therefore, we performed similar analyses categorizing the meta-analyses according to the number of events in trials in non-HIG publication venues. We also evaluated whether the results of trials published in HIG journals are differentially biased when these trials are the first to be published on a topic. We selected the meta-analyses where a trial from a HIG journal was published in the earliest calendar year among all trials included in the meta-analysis. Whenever more than one trial had been published in HIG journals in the earliest year, we selected the one with earliest PMID number. Then, that earliest HIG journal trial was compared against all other trials (including those subsequently published in HIG journals); and against all trials in other (non-HIG) publication venues. We also compared the effects of the trials published first in non-HIG journals vs all subsequently published trials. Similarly, we evaluated whether the latest trial published in a HIG journal had different results from other trials; in this analysis, we did not consider meta-analyses that had a single HIG journal trial and that trial had been published in the earliest calendar year. For these analyses, the tertile cut-offs of the number of events were calculated from the earliest HIG or non-HIG, or latest HIG journal trials only.
Finally, we evaluated whether bias is different for the three most influential journals. Specifically, we calculated sRORs for trials published in each one of the three journals compared with all other trials (including those from the other two journals); and compared with trials in other (non-HIG) publication venues only. Using the tertile event cut-offs of the main analysis (<40, 40-361, 4361), we formed three groups of meta-analyses according to the number of events in trials from the respective HIG journal for each journal-specific analysis. A sensitivity analysis was limited to meta-analyses where there was only a single trial published in a HIG journal.
The search for eligible studies and the data extraction were conducted independently by two investigators (K.C.M.S., E.E.). Discrepancies were resolved by consensus and arbitration by a third investigator (J.P.A.I.). Random-effects models were used for the calculation of the sROR estimates in all analyses [16] [17] [18] and heterogeneity between meta-analyses in each group was quantified with the I 2 statistic and its 95% CI. 19, 20 Tau-squared estimates were also calculated for the main analysis. Analyses were performed in STATA 10.1 (STATA Corp., College Station, TX, USA). P-values are two tailed.
Results

Compiled data
Overall, 249 Cochrane reviews and journal-based meta-analysis articles were assessed in depth for eligibility (details in Supplementary Figure S1 ), and 70 were deemed eligible (Supplementary References). There were 79 eligible meta-analyses (7 reviews had 41 eligible meta-analysis) ( Table 1, additional details  in Supplementary Table S1 ). One meta-analysis considered publications in English language only, three meta-analyses applied a minimum sample size criterion (thresholds of 30, 50 and 500 patients) but none used a threshold based on number of events, and no meta-analysis used a methodological quality score threshold for the inclusion of trials (Supplementary Table S2 ).
The eligible meta-analyses synthesized data from 1043 trials, of which 221 appeared in the three HIG journals (NEJM n ¼ 98, JAMA n ¼ 43, Lancet n ¼ 80). The other 822 trials came from other journals (n ¼ 785, 682 of which were from journals with assigned impact factors), abstracts (n ¼ 14), books (n ¼ 11), theses (n ¼ 5), personal communications (n ¼ 4) and company databases (n ¼ 3). Each meta-analysis included a median of two trials [interquantile range (IQR) 1-3) from HIG journals and seven (IQR 2-12) other trials. The median of the median (per meta-analysis) impact factors was 39.2 (IQR 28.4-50.0) for HIG and 4.4 (IQR 3.8-7.5) for other journals. None of the other journal venues had a higher impact factor than the three HIG Table 2 shows characteristics in groups split according to tertiles of the number of events in HIG trials. None of the trials from HIG journals in the first tertile (<40 events) were acknowledged by their authors to have been stopped early for benefit.
Comparison of effect sizes
In 46 meta-analyses, the point estimate of the effect of the new/experimental intervention was more favourable in trials published in HIG journals than in other publication venues (ROR41), whereas the opposite occurred in 33 meta-analyses. The comparison of effect sizes in trials published in HIG journals with trials in other venues depended on how large the trials were in HIG journals (P-for-trend < 0.001; Figure 1 ). For the first tertile (<40 events), the sROR was 1.64 (95% CI: 1.23-2.18, P ¼ 0.001), i.e. HIG journals showed considerably larger effects in favour of experimental interventions. When the analysis of the first tertile was limited to eight meta-analyses with equally small number of events (<40) in non-HIG trials, the sROR in HIG vs non-HIG trials was 1.80 (95% CI: 0.93-3.47, P ¼ 0.08). In the second tertile, the sROR was 1.18 (95% CI: 0.97-1.44, P ¼ 0.10) and in the third tertile, there was no difference for trials published in HIG journals compared with other trials [sROR 0.97 (95% CI: 0.90-1.04), P ¼ 0.38] (Figure 1 ). Estimates of I 2 (95% CI) (%) between meta-analyses were 0 (0-43), 42 (8-64) and 42 (8-64) for the three groups (heterogeneity P ¼ 0.98, 0.013 and 0.013), respectively. Respective tau-squared estimates were 0, 0.10 and 0.01. sRORs (95% CIs) for groups of meta-analyses according to tertiles of the number of events in trials published in non-HIG publication venues showed no trend of the effects [0.96 (0.79-1.18), 1.26 (1.00-1.59) and 1.01 (0.95-1.07) for <87, 87-363 and 4363 events, respectively, P-for-trend ¼ 0.75). When we used the same event cut-off for small trials from non-HIG journals as in trials from HIG journals (<40 events), the sROR of the comparison of HIG trials (of any size) vs small non-HIG trials was 1.12 (95% CI: 0.74-1.70, P ¼ 0.59). In the 46 meta-analyses where a non-HIG trial was published first, no difference was observed between the effect sizes in the early non-HIG trials and all other trials. Specifically, the sROR (95% CI) estimates were 0. In 67 meta-analyses (excluding 12 meta-analyses that had a single trial from a HIG journal and that trial was published in the earliest year), summary RORs indicated no differences between the latest-published trials in HIG journals and the other trials Results were similar when the latest trials from HIG journals were compared against non-HIG trials only (data not shown).
Journal-specific trends
The results of trials published in NEJM were far more favourable when these trials had <40 events, the difference was smaller when there were 40-361 events and no difference was observed when there were 4361 events in NEJM trials (P-for-trend < 0.001) ( Table 3) . A similar picture was present for trials from Lancet (P-for-trend ¼ 0.03). No such trend was seen for JAMA (P-for-trend ¼ 0.31); however, data were limited for this journal and two-factor ANOVA showed no difference in the pattern between the three journals that would be beyond chance (P ¼ 0.79). The results did not change substantially when HIG journal trials were compared against trials in other publication venues, excluding trials from other HIG journals (P-for-trend ¼ 0.002 for NEJM, 0.03 for Lancet, 0.20 for JAMA; P ¼ 0.70 for the three-journal comparison). Sensitivity analyses including meta-analyses with only one trial from each HIG journal gave similar results (data not shown).
Discussion
We found that small trials published in NEJM, JAMA and Lancet were more likely to display more favourable results for experimental interventions compared with trials in other publication venues. Other investigators have actually questioned whether there is any effect on mortality for this intervention and they attribute the effect to bias in poor-quality trials with no benefit in high-quality trials (relative risk 1.02). sizes were seen primarily for early small trials in these prominent journals. Therefore, the results of small trials with spectacular early promises for large treatment effects should be seen with great caution. Conversely, for large trials, effect estimates are likely to be more reliable. Small-study effects have been previously documented in the randomized trials literature. 25, 26 However, the results of our study provide further insight suggesting the possibility of a specific interaction with further exaggerated effects when the limited evidence from small trials appears in the most prestigious journals. Also, the inflation of effects in early randomized trials on particular interventions appears to be quite specific to these most prestigious journals. Some modest heterogeneity was seen in the two tertiles with higher events, but heterogeneity is difficult to determine in the tertile with lower events, because of the wide uncertainty in the ROR for single topics, when there is limited evidence. 27 The phenomenon where only a handful of journals publish the largest share of groundbreaking research is an oligopoly equivalent. 3 These very few journals have the power to significantly affect clinical science and practice. Prestigious journals continuously increase the number of citations they receive, 28, 29 other journals gradually fall even more behind, oligopoly is intensified and a bottleneck effect ensues in journal hierarchy. Prestigious journals will attract the submission of the most informative results, regardless of whether their editors favour publishing significant results or not. Thus it is not surprising that these results may be inflated, especially when small and early trials are involved, due to the winner's curse phenomenon. 3, 9 Also, the relationship between industry and journals has been documented and is apparently more prominent for prestigious journals. The publication of impressive findings, especially for new interventions, may increase a journal's income by reprints and advertisements, as well as its impact factor. 30, 31 In topics with significant publication bias, the true exaggeration of effects in prestigious journals might be even more striking than what we observed in our analysis. However, we should acknowledge that the larger effect sizes observed in small and early trials in prestigious journals may not always be wrong or inflated. Differences may reflect genuine variability in the treatment effects. 32 For example, early trials may evaluate populations where the effect sizes are expected to be larger and easier to discern in proofof-principle investigations. Late, large trials may be assessing populations and clinical settings with more questionable benefits, once effectiveness has been documented in small, early trials. However, we observed no trend for effect inflation in small trials published in other, non-HIG journals. Therefore, it is more likely that the more favourable results of trials in prestigious journals are indeed exaggerated. The inflation may be due to complex selection forces including publication 5, 6 and time-lag biases, 12 selective reporting of outcomes and analyses, 4 or early stopping of trials 8, 33 and these should be examined on a case-by-case basis. 34 Regardless, one should be extra cautious when a single small trial published in a prestigious journal heralds a highly effective new intervention. The effect may be non-existent or at least smaller. Replication of the proposed effects in additional trials is necessary for appropriate inferences for clinical practice. Also, all trials, large or small, and regardless of whether they are published in high-, moderate-or low-impact factor journals should be considered in inclusive meta-analyses that should be performed both prior to designing new trials as well as after a new trial has been published, in order to place the results in context. 35 Our study has limitations. First, our eligibility criteria for meta-analyses (binary outcomes pertaining to effectiveness only, availability of raw event data for trials) may limit the diversity of our sample, but only a small number of meta-analyses were excluded on the basis of these criteria. Second, several journals in the control group are also high impact. Top specialty journals also accept manuscripts at very low rates, and have impressive impact factors. However, the three HIG journals have outweighed others in impact factor consistently for a long time. Impact factor considerations may not have been so important for trials published several decades ago, but the very large majority of the trials we analysed were published at a time when the scientific world had been irrevocably sensitized to the impact factor. Third, meta-analysis effects are standardized to specific outcomes, but trials may present exaggerated results also by other ways, e.g. highlighting subgroup effects 36 or focusing on non-standardized post hoc analyses of composite outcomes. 37, 38 Thus exaggeration of effects in early, small trials may be even greater than we observed. Finally, we did not attempt to identify and correct any potential methodological imperfections in each meta-analysis. This would have been very difficult for a corpus including 41000 trials and such a wide array of clinical topics. Admittedly some of the inflated effects may reflect methodological shortcomings of specific trials. However, it is unlikely that trials published in prestigious journals would be of lower quality, even though the correlation between impact factor and reported quality is not strong. 39 Moreover, trial quality is difficult to sum in a single score 40 and associations of quality deficiencies with effect size suggest a relatively small impact (ROR approximately 1.10) 41 compared with what we observed. Acknowledging these caveats, our findings suggest the need for extra caution in interpreting impressive treatment effects in early small trials in prestigious journals.
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